Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva CEO to Meet Netanyahu With Blunt Message on Need for Cuts - Bloomberg
Teva's $4 Billion Medicine Faces Patent Judgment Day in U.S. - Bloomberg
Sandoz, Amneal and Rhodes join Teva in nationwide generic Adderall shortage as demand spikes
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Tags search | Ctech
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Drugmaker Teva makes $40B bid for rival Mylan
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
The Difficulties of Cloning a CEO - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Adderall Shortages Spread to 4 Pharmaceutical Companies Including Teva, Novartis - Bloomberg
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
A bottle of Teva Pharmaceutical Industries Ltd. Clonazepam medication... News Photo - Getty Images
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
